Metrics to compare | TPST | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTPSTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −2.8x | −0.4x | |
PEG Ratio | −0.01 | 0.00 | 0.00 | |
Price/Book | 22.9x | 1.8x | 2.6x | |
Price / LTM Sales | - | 73.4x | 3.1x | |
Upside (Analyst Target) | - | 101.9% | 47.5% | |
Fair Value Upside | Unlock | −3.3% | 5.9% | Unlock |
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.